The Japan Times - Fentanyl trade unravels

EUR -
AED 4.051657
AFN 71.711136
ALL 90.823351
AMD 397.762915
ANG 1.975246
AOA 1012.775429
ARS 1704.410242
AUD 1.627548
AWG 1.985834
AZN 1.877301
BAM 1.952607
BBD 2.222666
BDT 137.591121
BGN 1.956565
BHD 0.417337
BIF 3321.882818
BMD 1.103241
BND 1.42445
BOB 12.883758
BRL 6.251297
BSD 1.103496
BTN 104.197152
BWP 15.462488
BYN 3.314177
BYR 21623.523585
BZD 2.224897
CAD 1.572527
CDF 2554.00267
CHF 0.92447
CLF 0.028098
CLP 1105.863117
CNY 7.360548
CNH 7.362363
COP 3662.72702
CRC 495.700337
CUC 1.103241
CUP 26.549442
CVE 110.48899
CZK 24.405893
DJF 196.989092
DKK 7.479003
DOP 67.294348
DZD 151.381258
EGP 58.979123
ERN 16.548615
ETB 181.567437
FJD 2.509156
FKP 0.835031
GBP 0.834503
GEL 2.858008
GGP 0.835031
GHS 12.935511
GIP 0.835031
GMD 81.639623
GNF 9800.915413
GTQ 8.436091
GYD 230.869347
HKD 8.655218
HNL 29.747024
HRK 7.537304
HTG 145.067159
HUF 365.02659
IDR 20118.040917
ILS 3.548796
IMP 0.835031
INR 103.975502
IQD 1677.054422
IRR 2111313.671213
ISK 136.724431
JEP 0.835031
JMD 174.791165
JOD 0.782225
JPY 176.140702
KES 143.476496
KGS 96.462426
KHR 4501.223002
KMF 493.148479
KPW 992.917285
KRW 1473.361777
KWD 0.343626
KYD 0.921844
KZT 493.088228
LAK 24901.110629
LBP 99063.005239
LKR 367.937153
LRD 188.061882
LSL 18.701504
LTL 3.257584
LVL 0.667339
LYD 7.130759
MAD 10.962754
MDL 20.094228
MGA 5026.059145
MKD 61.594745
MMK 2317.108945
MNT 3977.915155
MOP 8.94032
MRU 44.739132
MUR 52.53656
MVR 16.990907
MWK 1918.249216
MXN 20.439189
MYR 4.507953
MZN 70.496471
NAD 18.701504
NGN 1482.281716
NIO 40.712881
NOK 11.213088
NPR 166.715643
NZD 1.995007
OMR 0.424853
PAB 1.103496
PEN 3.76404
PGK 5.048077
PHP 70.562765
PKR 305.900551
PLN 4.40646
PYG 6848.800958
QAR 4.020486
RON 5.352817
RSD 117.560262
RUB 91.308338
RWF 1636.621768
SAR 4.22068
SBD 8.933711
SCR 15.307363
SDG 663.602895
SEK 11.104915
SGD 1.41998
SHP 0.830722
SLE 25.429962
SLL 23134.416176
SOS 632.210586
SRD 41.360641
STD 22834.861249
STN 24.519803
SVC 9.679818
SYP 14344.339844
SZL 18.696099
THB 37.372286
TJS 10.204942
TMT 3.861343
TND 3.319097
TOP 2.65634
TRY 55.544053
TTD 7.509064
TWD 36.287145
TZS 2929.265733
UAH 50.29562
UGX 4557.547576
USD 1.103241
UYU 44.726863
UZS 13302.743558
VES 1007.125816
VND 28381.426325
VUV 132.742059
WST 3.100754
XAF 655.957
XAG 0.022571
XAU 0.000284446398
XCD 2.981564
XCG 1.99371
XDR 0.780049
XOF 655.957
XPF 119.331742
YER 260.97197
ZAR 18.686148
ZMK 9930.495619
ZMW 22.617266
ZWL 355.243152
SSP 6559.188284
MXV 2.295346
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%


Fentanyl trade unravels




Fentanyl, a synthetic opioid up to 50 times more powerful than heroin, has been at the centre of a catastrophic overdose crisis. After years of relentless expansion, the market that once claimed tens of thousands of lives annually is contracting. Preliminary data from the United States Centers for Disease Control and Prevention (CDC) indicate that estimated drug overdose deaths fell to about 80,000 in 2024, a 27 per cent decline from the record of more than 110,000 in 2023, signalling the largest one‑year drop in modern history. This article examines why the fentanyl business is faltering, exploring the interlocking impacts of supply‑chain disruption, international diplomacy, law‑enforcement operations and public‑health initiatives.

From Peak to Downturn
During the early 2020s, illicitly manufactured fentanyl flooded the North American drug market, becoming the leading cause of overdose deaths. The pandemic exacerbated the situation: social isolation and disrupted addiction treatment services contributed to a spike of nearly 110,000 U.S. overdose deaths in 2023. Most of those deaths involved fentanyl, which dealers used to replace or adulterate heroin, counterfeit prescription pills and cocaine. Yet by 2024 the tide had turned. CDC data show that overdose deaths fell by roughly 30,000 in one year, and preliminary numbers for 2025 suggest the decline is continuing. The decrease extends across most U.S. states, with notable reductions in Ohio and West Virginia. Such a sustained downward trend had not been seen in decades and prompted researchers to look beyond domestic policy interventions for an explanation.

Supply‑Chain Disruption and China’s Crackdown
One of the most significant drivers of the decline appears to be a disruption in the global supply of fentanyl and its precursors. Researchers analysing death trends in the United States and Canada found evidence of a sudden shortage of fentanyl on illicit markets beginning in mid‑2023. A Science journal study led by scholars at Stanford and the University of Maryland concluded that Chinese enforcement actions against chemical suppliers have curtailed exports of fentanyl precursors. Officials in Beijing shut down hundreds of companies, removed tens of thousands of online advertisements and arrested about 300 people after agreements with Washington to restrict the trade. The research suggests these moves reduced the availability of 4‑fluoroisobutyryl fentanyl and other precursors, causing the purity of seized fentanyl to fall and the price to rise. According to the DEA’s 2025 National Drug Threat Assessment, some Chinese suppliers have become wary of shipping controlled chemicals, aware that their government is enforcing updated counter‑narcotics treaties. Mexican fentanyl cooks report difficulty obtaining key precursors and are increasingly relying on designer chemicals to circumvent regulations.

Cartel Disruption and Enforcement
While precursor shortages have choked production, targeted law‑enforcement operations have also shaken the industry. White papers from the National Security Data and Policy Institute detail how the capture of Ovidio Guzmán López — a senior Sinaloa Cartel figure and son of Joaquín "El Chapo" Guzmán — in 2023 destabilised the cartel’s synthetic‑drug division. Experts point to a correlation between cartel ‘decapitation’ operations and sharp but temporary declines in fentanyl seizures and overdose deaths. The killing of Nemesio Oseguera Cervantes, leader of the Jalisco New Generation Cartel in late 2025, likewise rattled the market, although researchers caution that rival factions can quickly reconstitute production. The National Drug Threat Assessment notes that the Sinaloa and Jalisco cartels continue to dominate fentanyl production, but they face greater risk as Mexican and U.S. authorities cooperate to target laboratories and intercept shipments at the southwest border. Seizures at border crossings dropped from 29,000 kilograms in 2023 to 23,000 kilograms in 2024, reinforcing evidence of a supply contraction.

Public‑Health Measures and Changing Behaviour
The contraction of the fentanyl trade has amplified the effect of public‑health interventions. Increased distribution of the overdose‑reversal drug naloxone, expansion of medication‑assisted treatment programmes and billions of dollars in opioid settlement funds have collectively improved survival rates. Harm‑reduction services such as supervised consumption sites and drug‑checking kits have proliferated in major cities, allowing users to detect dangerous adulterants like xylazine and medetomidine. Younger Americans appear less likely to initiate opioid use than previous cohorts, and some long‑term users have died or shifted consumption patterns. These behavioural changes mean that a shrinking pool of susceptible individuals is exposed to an increasingly fragmented drug supply.

An Evolving Drug Market
Despite the current downturn, the illicit drug market is far from static. The DEA warns that declining fentanyl purity does not equate to reduced danger. To compensate for shortages, traffickers are mixing fentanyl with veterinary tranquilizers and new synthetic opioids such as nitazenes, which can be even more potent. The National Security Data and Policy Institute notes that precursor chemicals still arrive in Mexico’s Pacific ports such as Manzanillo, and cartels are diversifying sourcing through India and alternative trans‑shipment points. According to the DEA, the presence of xylazine in seized powder has risen steadily since 2020, increasing the risk of fatal respiratory depression and flesh‑rotting wounds. Nitazene analogues and other novel substances are appearing in toxicology reports at an accelerating rate in 2026, underscoring how quickly manufacturers pivot when confronted with enforcement pressure.

The sharp decline in fentanyl‑related deaths offers a glimmer of hope after years of escalating tragedy, but it is not a definitive victory. The current contraction appears to be driven primarily by disruptions in precursor supply, strategic cartel‑targeting operations and strengthened public‑health responses. Yet the same agility that allowed traffickers to flood markets with fentanyl enables them to adapt to enforcement, shifting to new chemicals, routes and business models. Sustained reductions in opioid mortality will require international cooperation to control chemical exports, continued pressure on manufacturing networks, wider access to treatment and harm‑reduction services, and public education to deter drug initiation. As policy makers debate how to allocate resources, the lesson of the fentanyl collapse is clear: comprehensive, co‑ordinated action across borders and disciplines can save lives.